UMILi032-A
General
Cell Line |
|
| hPSCreg name | UMILi032-A |
| Cite as: | UMILi032-A |
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
HIHDNDi001-A (A30P-3, SNCA3, Tue_020_A) Donor's gene variants: SNCA, SNCA, SNCA Donor diseases: autosomal dominant Parkinson disease 1 HIHDNDi001-B (A30P-4, SNCA4, Tue_020_B) Donor's gene variants: SNCA, SNCA, SNCA Donor diseases: autosomal dominant Parkinson disease 1 UNIFEi002-A (UNIFEi013-A, UniFei013-A, MARPiPSCA1N13, iPSca1N13) Donor diseases: Spinocerebellar Ataxia Type 1 HDZi003-A (hiPSC NP0038) Donor's gene variants: TMEM43 Donor diseases: arrhythmogenic right ventricular dysplasia 5 RNRMUi005-A (EB-iPSC-d4, RDEB-iPSC-d4) Donor diseases: Epidermolysis Bullosa Simplex recessive dystrophic epidermolysis bullosa |
| Last update | 30th November 2025 |
| User feedback | |
Provider |
|
| Generator | University of Milan (UMIL) |
| Derivation country | Italy |
External Databases |
|
| BioSamples | SAMEA118715424 |
General Information |
|
| Publications | |
| * Is the cell line readily obtainable for third parties? |
No |
Donor Information
General Donor Information |
|
| Sex | male |
| Age of donor (at collection) | 15-19 |
| Ethnicity | Central European |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
External Databases (Donor) |
|
| BioSamples | SAMEA118715425 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
| If you do not hold the Donor Consent Form, do you know who does? | Yes |
| Confirm that consent was obtained by a qualified professional | Yes |
| Has the donor been informed about how her/his data will be protected? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| * Does consent expressly prevent the derivation of pluripotent stem cells? | No |
| * Does consent pertain to a specific research project? | Yes |
| Details on restriction to research project | The generated iPS cell line can be used only by Prof. Fornasari in the context of the project entitled: ‘Sviluppo di nuovi modelli sperimentali per lo studio della Sindrome da ipoventilazione Centrale Congenita (CCHS, Sindrome di Ondine)’. |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | Yes |
| How may genetic information associated with the cell line be accessed? | No information |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Meyer Children’s Hospital, Florence, Italy |
| Approval number | 7/2015 |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
| Source cell type | |
| Source cell origin |
The structure on the upper limb, between the elbow and the wrist.
Synonyms
|
| Age of donor (at collection) | 15-19 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Genes | |
| Is reprogramming vector detectable? |
No |
| Methods used |
RT-PCR
|
| Files and images showing reprogramming vector expressed or silenced | |
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
EDTA
|
| CO2 Concentration | 5 % |
| Medium |
Essential 8™ Flex
|
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| POU5F1 (OCT-4) |
Yes |
|||||
| SSEA-4 |
Yes |
|||||
| NANOG |
Yes |
Morphology pictures
Morphology_32A.tiff
Representative image of iPSC colonies
Differentiation Potency
In vitro directed differentiation
Morphology
qPCR_Trilineage_32A.tif
Trilineage qPCR
Protocol or reference
stemdiff trilineage differentiation kit.pdf
STEMdiff Trilineage Differentiation Kit
In vitro directed differentiation
| Marker | Expressed |
| TBXT (BRACHYURY) |
Yes |
| NCAM1 |
Yes |
Morphology
qPCR_Trilineage_32A.tif
Trilineage qPCR
Protocol or reference
stemdiff trilineage differentiation kit.pdf
STEMdiff Trilineage Differentiation Kit
In vitro directed differentiation
| Marker | Expressed |
| PAX6 |
Yes |
| OTX2 |
Yes |
Morphology
qPCR_Trilineage_32A.tif
Trilineage qPCR
Protocol or reference
stemdiff trilineage differentiation kit.pdf
STEMdiff Trilineage Differentiation Kit
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.